In Vivo Diagnosis of Gene Localization and Expression by Nuclear Medicine Modality
In Vivo Diagnosis of Gene Localization and Expression by Nuclear Medicine Modality
批准号:
13670965
负责人:
NAKAMURA Kayoko
金额:
$2.56万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2003
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The aim of this investigation is to develop nuclear medicine techniques for non-invasive diagnosis of gene localization and expression. Gene here means the one injected for gene therapy or the other over-expressed due to the disease. Using human epidermoid tumor cell line ; KB-31 and its mdr-1 transfected cell line ; KB-G2 carried out the study. By co-working with Dr. Donald J Hnatowich, Professor of Massachusetts Medical School, the following results were obtained;1. Antisense (AS) and sense (S) oligonucleotides related to mdr-1 were synthesized and modified (all phosphothiolated) and then, labeled with Tc-99m via MAG3 or HYNIC ligands. Tc-99m-AS and Tc-99m-S were obtained with high specific activity without loosing their antisense-binding affinity.2. KB-31 or KB-G2 were treated with AS or S, followed by incubation with Tc-99m-MIBI, which is to evaluate P-glycoprotein (mdr-1 expression) function. The KB-G2 treated with AS suppressed the P-gp function, while it was not shown in KB-G2 treated by S. KB-31 did not show any influence by treating with AS or S. These results indicated the antisense effect of AS oligonucleiotied we used.3. Tc-99m-AS was accumulated in KB-G2 but not in KB-31, while Tc-99m-S was not taken up either in KB-G2 or KB-31. These results indicated that AS was accumulated into the cell by antisense effect.4. Tc-99m-AS or Tc-99m-S was injected into the mice bearing KB-G2 or KB-31. The uptake of Tc-99m-AS in the KB-G2 tumor was significantly higher than that in the KB-31 tumors. Tc-99m-AS uptake in KB-G2 tumor was significantly higher than Tc-99m-S. These results indicated that Tc-99m-AS was localized into the mdr-1-tumors specifically by antisense erect.All these results would lead the success for the antisense imaging.
期刊论文(80)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
中村 佳代子: "遺伝子と臨床核医学(9):クローン、クローニング、cDNA"臨床核医学. 35(2). 27-29 (2002)
Kayoko Nakamura:“基因与临床核医学 (9):克隆、克隆、cDNA”临床核医学 35(2) (2002)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kayoko Nakamura: "Can Tc-99m-MIBI assess MDR-modulators?"European Journal of Nuclear Medicine. 29(S1). S381 (2002)
Kayoko Nakamura:“Tc-99m-MIBI 可以评估 MDR 调节剂吗?”欧洲核医学杂志。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
中村 佳代子<分担>: "Sentinel Node Navigation-癌治療への新しい展開-センチネルリンパ節の核医学的検出に用いる放射性医薬品"金原出版株式会社. 296 (2002)
Kayoko Nakamura <贡献者>:“前哨淋巴结导航 - 癌症治疗的新进展 - 用于前哨淋巴结核医学检测的放射性药物” Kanehara Publishing Co., Ltd. 296 (2002)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
中村 佳代子: "医療現場は科学の実地教育現場-放射線医学教育を通して科学的な考え方を育てる-"広領域教育. 52. 53-57 (2003)
Kayoko Nakamura:“医疗场所是实用的科学教育场所 - 通过放射学教育发展科学思维”广泛学科教育。52. 53-57 (2003)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nakamura K.: "Can Tc-99m-HL91 uptakes in the tumour predict the response of radiotherapy?"European Journal of Nuclear Medicine. 28. 1259 (2001)
Nakamura K.:“肿瘤中 Tc-99m-HL91 的摄取能否预测放射治疗的反应?”欧洲核医学杂志。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 79 条
Optical and Nuclear Imaging of Tumor-related genes
-
批准号:19591434
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2007
-
负责人:NAKAMURA Kayoko
-
依托单位:
Gene Imaging for Studying Pharmacokinetics of Gene in Vivo at the Real Time
-
批准号:16591225
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2004
-
负责人:NAKAMURA Kayoko
-
依托单位:
Development of Nuclear Medicine Modality for Selecting Cancer Therapy and for Predicting Therapeutic Efficacy from Molecular Biological Points of View
-
批准号:11670912
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:1999
-
负责人:NAKAMURA Kayoko
-
依托单位:
Modification of Multidrug Resistance by Magnetic Exposure Indicated from the Point of View of Nuclear Medicine
-
批准号:09670954
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.98万
-
财政年份:1997
-
负责人:NAKAMURA Kayoko
-
依托单位:
Molecular Biological Approach towards Efficient Radioimmunotherapy
-
批准号:07671027
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.47万
-
财政年份:1995
-
负责人:NAKAMURA Kayoko
-
依托单位:
Pharmacokinetic Study of Targeting Tumors with Radio-and Drug-conjugated Monoclonal Antibody
-
批准号:05670785
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1993
-
负责人:NAKAMURA Kayoko
-
依托单位:
Biochemical and Immunological Characterization of Tumors by Immunoscintigraphy
-
批准号:63570496
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1988
-
负责人:NAKAMURA Kayoko
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于中国散裂中子源伴生质子束的医用同位素Tc-99m产生研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:敬罕涛
-
依托单位:
表面修饰碳纳米管对Tc-99m同位素分离纯化性能的影响研究
-
批准号:CSTB2023NSCQ-BSX0034
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2023
-
负责人:陈建伟
-
依托单位:
用于肿瘤诊断和个性化治疗的Tc-99m/Re-188标记的σ2受体放射性药物研究
-
批准号:21471019
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2014
-
负责人:贾红梅
-
依托单位:
Tc-99m标记的σ2受体肿瘤分子探针的研究
-
批准号:21071023
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:贾红梅
-
依托单位:
Tc-99m标记的含有双生物还原基团的乏氧显像剂研究
-
批准号:21071010
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:褚泰伟
-
依托单位:
利用纳米颗粒为载体改进Tc-99m中枢神经受体显像剂进脑量的研究
-
批准号:20871021
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2008
-
负责人:刘伯里
-
依托单位:
Tc-99m标记的叶酸受体肿瘤显像剂的研究
-
批准号:20701004
-
项目类别:青年科学基金项目
-
资助金额:15.0万元
-
批准年份:2007
-
负责人:陆洁
-
依托单位:
Tc-99m标记的σ受体肿瘤显像剂的研究
-
批准号:20501004
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2005
-
负责人:贾红梅
-
依托单位:
Tc-99m标记的CNS斑块等受体显像剂及介导系统的研究
-
批准号:20471011
-
项目类别:面上项目
-
资助金额:22.0万元
-
批准年份:2004
-
负责人:刘伯里
-
依托单位:
Tc-99m标记单克隆抗体的化学研究
-
批准号:29070033
-
项目类别:面上项目
-
资助金额:3.0万元
-
批准年份:1990
-
负责人:刘元方
-
依托单位: